Compare CTSH & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSH | RMD |
|---|---|---|
| Founded | 1994 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 36.4B |
| IPO Year | 1998 | 1995 |
| Metric | CTSH | RMD |
|---|---|---|
| Price | $85.66 | $252.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $86.07 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 4.5M | 916.6K |
| Earning Date | 02-04-2026 | 01-29-2026 |
| Dividend Yield | ★ 1.45% | 0.96% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | 4.32 | ★ 9.77 |
| Revenue | ★ $20,857,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $8.99 | $9.85 |
| Revenue Next Year | $4.72 | $7.36 |
| P/E Ratio | ★ $19.85 | $25.68 |
| Revenue Growth | 7.44 | ★ 9.36 |
| 52 Week Low | $65.15 | $199.92 |
| 52 Week High | $90.82 | $293.81 |
| Indicator | CTSH | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 57.53 |
| Support Level | $83.51 | $240.00 |
| Resistance Level | $85.77 | $250.15 |
| Average True Range (ATR) | 1.60 | 3.90 |
| MACD | -0.30 | 1.13 |
| Stochastic Oscillator | 75.39 | 90.37 |
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.